VMT-a-NET is under clinical development by Perspective Therapeutics and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase II drugs for Neuroendocrine Tumors have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VMT-a-NET’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VMT-a-NET overview

VMT-a-NET is under development for the treatment of neuroendocrine tumors, medullary thyroid cancer, neuroblastoma, pheochromocytomas, paraganglioma, renal cell carcinoma (RCC), head and neck cancer and small-cell lung cancer. The drug candidate comprises 212 pb labelled peptide conjugate that acts by targeting cells expressing somatostatin receptor type 2 (SST2R). It is administered through intravenous route.

Perspective Therapeutics overview

Perspective Therapeutics, formerly known as Isoray, Inc., is a medical technology company. It specializes in the development and distribution of isotope-based personalized brachytherapy products and devices for advanced cancer treatments. The company’s core product is the Cesium-131 brachytherapy seed, a unique radioisotope seed used in the treatment of various cancers, including prostate, brain, head and neck, and lung cancers. Brachytherapy involves placing the radiation sources close to the tumor site to destroy the cancer cells. Perspective Therapeutics serves medical centers, hospitals, and clinics. It operates primarily in the US. Perspective Therapeutics is headquartered in Richland, Washington, the US.

For a complete picture of VMT-a-NET’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.